MacroGenics (MGNX) clinical trials: pipeline and status changes, no readout expected in the next 12 months
Trials that could report in the next 12 months: 0BiopharmaCTG
Catalyst timeline
No upcoming catalysts tracked for MGNX. Estimated readout windows appear automatically as tracked trials approach their registered completion dates.
Pipeline
| Program | Phase | Status | Primary completion | Trial |
|---|---|---|---|---|
| A Study of MGC026 in Participants With Advanced Solid Tumors | Phase 1 | Recruitingstill enrolling patients | NCT06242470 | |
| A Study of MGD024 in Patients With Relapsed or Refractory Hematologic … | Phase 1 | Active Not Recruitingenrolled, still running | NCT05362773 | |
| A Study of MGC028 in Participants With Advanced Solid Tumors | Phase 1 | Recruitingstill enrolling patients | NCT06723236 | |
| A Study of Lorigerlimab in Participants With Advanced Solid Tumors | Phase 2 | Recruitingstill enrolling patients | NCT06730347 |
Status-change history
Every ClinicalTrials.gov change recorded for MGNX's trials — a running history no other tracker shows.
No status changes detected yet for this ticker.
Frequently asked
When is MGNX's next PDUFA date?
No disclosed PDUFA date is currently tracked for this ticker.
What phase is MGNX's lead program in?
Phase 2 — recruiting.
Where does this data come from?
ClinicalTrials.gov v2 API (trial status + diffs) and company 8-K/press-release disclosures (PDUFA dates). Every number links to its source.